Seasonal allergic rhinitis

Recent Patents on Inflammation and Allergy Drug Discovery

Volumn 2, Issue 3, 2008, Pages 175-185

  Leung, Alexander K C ^a,c   Hon, Kam Lun E ^b  

^a UNIVERSITY OF CALGARY   (Canada)

^b CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

^c NONE   (Canada)

Author keywords

Immunotherapy; In vitro tests for total and specific IgE; Nasal cytology; Pharmacotherapy; RAST; Seasonal allergic rhinitis; Skin tests

Indexed keywords

ALLERGEN; ANTIHISTAMINIC AGENT; CHOLINERGIC RECEPTOR BLOCKING AGENT; CORTICOSTEROID; CROMOGLYCATE DISODIUM; DECONGESTIVE AGENT; IMMUNOLOGIC AGENT; LEUKOTRIENE RECEPTOR BLOCKING AGENT; MAST CELL STABILIZER; NEDOCROMIL SODIUM; PLACEBO; UNCLASSIFIED DRUG; GLUCOCORTICOID;

ALLERGIC CONJUNCTIVITIS; ALLERGIC RHINITIS; ANAPHYLAXIS; ANGIONEUROTIC EDEMA; BLURRED VISION; BURNING SENSATION; CONSTIPATION; CYTOLOGY; DIZZINESS; DRUG EFFICACY; DRUG INDUCED HEADACHE; DRUG PENETRATION; DRUG POTENCY; DRUG TOLERABILITY; DRY NOSE; ENZYME LINKED IMMUNOSORBENT ASSAY; EPISTAXIS; GASTROINTESTINAL SYMPTOM; HAY FEVER; HEART ARRHYTHMIA; HUMAN; IMMUNOFLUORESCENCE TEST; IMMUNOTHERAPY; INCIDENCE; INJECTION SITE SWELLING; NAUSEA; NOSE CONGESTION; NOSE DISEASE; OCULAR PRURITUS; ORAL MUCOSAL DISEASE; PATHOGENESIS; PATIENT COMPLIANCE; PREVALENCE; PRIORITY JOURNAL; PRURITUS; QT PROLONGATION; REVIEW; RHINITIS; RHINITIS MEDICAMENTOSA; SIDE EFFECT; SKIN TEST; SNEEZING; STEROID THERAPY; SYMPTOMATOLOGY; TASTE DISORDER; TORSADE DES POINTES; URINE RETENTION; URTICARIA; XEROSTOMIA; HOSPITALIZATION; IMMUNOLOGY; METHODOLOGY; PATENT; PATHOPHYSIOLOGY; QUALITY OF LIFE; TIME;

GLUCOCORTICOIDS; HISTAMINE ANTAGONISTS; HUMANS; IMMUNOTHERAPY; PATENTS AS TOPIC; QUALITY OF LIFE; RHINITIS, ALLERGIC, SEASONAL; SEVERITY OF ILLNESS INDEX; TIME FACTORS;

EID: 61449365680     PISSN: 1872213X     EISSN: None     Source Type: Journal    
DOI: 10.2174/187221308786241965     Document Type: Review

References (103)

1. Leung AK, Bowen TJ. Seasonal allergic rhinitis and food allergy. In: Bergman AB, Ed. Twenty Common Problems in Pediatrics. New York, McGraw Hill 2001; 219-233.
2. Gergen PJ, Turkeltaub PC. The association of individual allergen reactivity with respiratory disease in a national sample: Data from the second National Health and Nutrition Examination Survey. 1976-1980 (NHANES II). J Allergy Clin Immunol 1992; 90: 579-588.
3. Sheikh A, Panesar SS, Dhami S, et al. Seasonal allergic rhinitis in adolescents and adults. Clin Evid 2005; 14: 684-695.
4. Selnes A, Nystad W, Bolle R, et al. Diverging prevalence trends of atopic disorders in Norwegian children. Results from three crosssectional studies. Allergy 2005; 60: 894-899.
5. Verlato G, Corsico A, Villani S, et al. Is the prevalence of adult asthma and allergic rhinitis still increasing? Results of an Italian study. J Allergy Clin Immunol 2003; 111: 1232-1238.
6. Seth D, Secord E, Kamat D. Allergic rhinitis. Clin Pediatr 2007; 46: 401-407.
7. Simons FE. Allergic rhinitis and associated disorders. In: McMillan JA, Feigin RD, DeAngelis C, et al. Eds. Oski's Pediatrics: Principles & Practice. Philadelphia, Lippincott Williams & Wilkins 2006; 2428-2432.
8. Leung AK, Kamat D. Clinical manifestations of food allergy. In: Columbus F, Ed. Food Allergies: New Research. New York, Nova Science Publishers, Inc. (in press).
9. Milgrom H, Leung DY. Allergic rhinitis. In: Kliegman RM, Behrman RE, Jenson HB, et al. Eds. Nelson Textbook of Pediatrics. Philadelphia, Saunders Elsevier 2007; 949-952.
10. Leung AK, Robson WL. Breastfeeding. In: Carter LV, Ed. Child Nutrition Research Advances. New York, Nova Science Publishers, Inc. (in press).
11. Mahr TA, Sheth K. Update on allergic rhinitis. Pediatr Rev 2005; 26: 278-282.
12. Rosenwasser L. New insights into the pathophysiology of allergic rhinitis. Allergy Asthma Proc 2007; 28: 10-15.
13. Jones N. Allergic rhinitis: A etiology, predisposing and risk factors. Rhinology 2004; 42: 49-56.
14. Pawankar R. Inflammatory mechanisms in allergic rhinitis. Curr Opin Allergy Clin Immunol 2007; 7: 1-4.
15. Lehman JM, Blaiss MS. Selecting the optimal oral antihistamine for patients with allergic rhinitis. Drugs 2006; 66: 2309-2319.
16. Leung AK, Robson WL. Sneezing. J Otolargyngol 1994; 23: 125-129.
17. Naclerio R. Intranasal corticosteroids reduce ocular symptoms associated with allergic rhinitis. Otolaryngol Head Neck Surg 2008; 138: 129-139.
18. Quillen DM, Feller DB. Diagnosing rhinitis: Allergic vs. nonallergic. Am Fam Physician 2006; 73: 1583-1590.
19. Bousquet J, van Cauwenberge P, Khaltaev N. Allergic rhinitis and its impact on asthma. J Allergy Clin Immunol 2001; 108(5): S147-S334.
20. Schneiderman H, Leung AK. Bilateral nasal polyps. Consultant Pediatrician 2003; 2: 323-328.
21. Leung AK, Hon KL, Robson WL. Atopic dermatitis. Adv Pediatr 2007; 54: 241-273.
22. Corren J. Allergic rhinitis and asthma: How important is the link? J Allergy Clin Immunol 1997; 99: S781-S786.
23. Smart BA. The impact of allergic and nonallergic rhinitis on pediatric sinusitis. Curr Allergy Asthma Rep 2006; 6: 221-227.
24. Berger WE. Allergic rhinitis in children: Diagnosis and management strategies. Pediatr Drugs 2004; 6: 233-250.
25. Ng DK, Chan CH, Hwang GY, et al. A review of the roles of allergic rhinitis in childhood obstructive sleep apnea syndrome. Allergy Asthma Proc 2006; 27: 240-242.
26. Ferguson BJ. Influences of allergic rhinitis on sleep. Otolaryngol Head Neck Surg 2004; 130: 17-29.
27. Kremer B. Quality of life scales in allergic rhinitis. Curr Opin Allergy Clin Immunol 2004; 4: 171-176.
28. Berger WE. Pediatric allergic rhinitis: Antihistamine selection. Clin Pediatr 2005; 44: 655-664.
29. Bahls C. In the clinic. Allergic rhinitis. Ann Intern Med 2007; 146: ITC4-1ITC-16.
30. Scadding GK, Durham SR, Mirakian R, et al. BSACI guidelines for the management of allergic and non-allergic rhinitis. Clin Exp Allergy 2008; 38: 19-42.
31. Gendo K, Larson EB. Evidence-based diagnostic strategies for evaluating suspected allergic rhinitis. Ann Intern Med 2004; 140: 278-289.
32. Montoro J, Sastre J, Jáuregui I, et al. Allergic rhinitis: Continuous or on demand antihistamine therapy? J Investig Clin Immunol 2007 17(Suppl 2): 21-27.
33. Plaut M, Valentine MD. Allergic rhinitis. N Engl J Med 2005; 353: 1934-1944.
34. Bachert C, van Cauwenberge P. Desloratadine treatment for intermittent and persistent allergic rhinitis: A review. Clin Ther 2007; 29: 1795-1802.
35. Canonica GW, Tarantini F, Compalati E, et al. Efficacy of desloratadine in the treatment of allergic rhinitis: A meta-analysis of randomized, double-blind, controlled trials. Allergy 2007; 62: 359-366.
36. Keith PK, Luciuk G. Effectiveness of desloratadine 5 mg once daily in patients with symptoms of seasonal allergic rhinitis: Results of a Canadian multicenter, open-label trial. Clin Ther 2007; 29: 419-426.
37. Lee TA, Pickard AS. Meta-analysis of azelastine nasal spray for the treatment of allergic rhinitis. Pharmacotherapy 2007; 27: 852-859.
38. Meltzer EO, Hampel FC, Ratner PH, et al. Safety and efficacy of olopatadine hydrochloride nasal spray for the treatment of seasonal allergic rhinitis. Ann Allergy Asthma Immunol 2005; 95: 600-606.
39. Patel P, D'Andrea C, Sacks HJ. Onset of action of azelastine nasal spray compared with mometasone nasal spray and placebo in subjects with seasonal allergic rhinitis evaluated in an environmental exposure chamber. Am J Rhinol 2007; 21: 499-503.
40. Pleskow W, Grubbe R, Weiss S, et al. Efficacy and safety of an extended-release formulation of desloratadine and pseudoephedrine vs the individual components in the treatment of seasonal allergic rhinitis. Ann Allergy Immunol 2005; 94: 348-354.
41. Lai L, Casale TB, Stokes J. Pediatric allergic rhinitis: Treatment. Immunol Clin North Am 2005; 25: 283-299.
42. Herman H. Once-daily administration of intranasal corticosteroids for allergic rhinitis: A comparative review of efficacy, safety, patient preference, and cost. Am J Rhinol 2007; 21: 70-79.
43. Fokkens WJ, Jogi R, Reinartz S, et al. Once daily fluticasone furoate nasal spray is effective in seasonal allergic rhinitis caused by grass pollen. Allergy 2007; 62: 1078-1084.
44. Kaari J. The role of intranasal corticosteroids in the management of pediatric allergic rhinitis. Clin Pediatr 2006; 45: 697-704.
45. DeWester J, Philpot EE, Westlund RE, et al. The efficacy of intranasal fluticasone propionate in the relief of ocular symptoms associated with seasonal allergic rhinitis. Allergy Asthma Proc 2003; 24: 331-337.
46. Kaiser HB, Naclerio RM, Given J, et al. Fluticasone furoate nasal spray: A single treatment option for the symptom of seasonal allergic rhinitis. J Allergy Clin Immunol 2007; 119: 1430-1437.
47. Martin BG, Ratner PH, Hampel FC, et al. Optimal dose selection of fluticasone furoate nasal spray for the treatment of seasonal allergic rhinitis in adults and adolescents. Allergy Asthma Proc 2007; 28: 216-225.
48. van Cauwenberge P, Bachert C, Passalacqua G, et al. Consensus statement on the treatment of allergic rhinitis. European Academy of Allergology and Clinical Immunology. Allergy 2000; 55: 116-134.
49. Task Force on Allergic Disorders. The Allergy Report, Vol. 1. Milwaukee, WI: American Academy of Allergy, Asthma and Immunology, 2000. http://www.theallergyreport.com accessed 8 May 2008.
50. Mullol J, Lopez E, Roca-Ferrer J, et al. Effects of topical antiinflammatory drugs on eosinophil survival primed by epithelial cells. Additive effect of glucocorticoids and nedocromil sodium. Clin Exp Allergy 1997; 27: 1432-1441.
51. Weiner JM, Abramson MU, Puy RM. Intranasal corticosteroids versus oral H1 receptor antagonists in allergic rhinitis: Systematic review of randomized controlled trials. BMJ 1998; 317: 1624-1629.
52. Bernstein DI, Levy AL, Hampel FC, et al. Treatment with intranasal fluticasone propionate significantly improves ocular symptoms in patients with seasonal allergic rhinitis. Clin Exp Allergy 2004; 34: 952-957.
53. Gawchik SM, Lim J. Comparison of intranasal triamcinolone acetonide with oral loratadine in the treatment of seasonal ragweedinduced allergic rhinitis. Am J Manag Care 1997; 3: 1052-1058.
54. Yanez A, Rodrigo GJ. Intranasal corticosteroids versus topical H1 receptor antagonists for the treatment of allergic rhinitis: A systematic review with meta-analysis. Ann Allergy Asthma Immunol 2002; 89: 479-484.
55. Pullerits T, Praks L, Ristoja V, et al. Comparison of a nasal glucocorticoid, antileukotriene, and a combination of antileukotriene and antihistamine in the treatment of seasonal allergic rhinitis. J Allergy Clin Immunol 2002; 109: 949-955.
56. Máspero JF, Rosenblut A, Finn A Jr, et al. Safety and efficacy of fluticasone furoate in pediatric patients with perennial allergic rhinitis. Otolarynogol Head Neck Surg 2008; 138: 30-37.
57. McCormack PL, Scott LJ. Fluticasone furoate. Intranasal use in allergic rhinitis. Drugs 2007; 67: 1905-1915.
58. Blaiss MS. Safety considerations of intranasal corticosteroids for the treatment of allergic rhinitis. Allergy Asthma Proc 2007; 28: 145-152.
59. Rosenblut A, Bardin PG, Muller B, et al. Long-term safety of fluticasone furoate nasal spray in adults and adolescents with perennial rhinitis. Allergy 2007; 62: 1071-1077.
60. Bielory L, Blaiss M, Fineman SM, et al. Concerns about intranasal corticosteroids for over-the-counter use: Position statement of the Joint Task Force for the American Academy of Allergy, Asthma and Immunology and the American College of Allergy, Asthma and Immunology. Ann Allergy Asthma Immunol 2006; 96: 1-12.
61. Meltzer EO. Allergic rhinitis: Managing the pediatric spectrum. Allergy Asthma Proc 2006; 27: 2-8.
62. Grainger J, Drake-Lee A. Montelukast in allergic rhinitis: A systematic review and meta-analysis. Clin Otolaryngol 2006; 31: 360-367.
63. Ho CY, Tan CT. Comparison of antileukotrienes and antihistamines in the treatment of allergic rhinitis. Am J Rhinol 2007; 21: 439-443.
64. Hon KLE, Leung TF. Killing many birds with one stone. HK J Pediatr 2008; 13: 135-138.
65. Razi C, Bakirtas A, Harmanci K, et al. Effect of montelukast on symptoms and exhaled nitric oxide levels in 7- to 14-year-old children with seasonal allergic rhinitis. Ann Allergy Asthma Immunol 2006; 97: 767-774.
66. Storms W. Update on montelukast and its role in the treatment of asthma, allergic rhinitis and exercise-induced bronchoconstriction. Expert Opin Pharmacother 2007; 8: 2173-2187.
67. Nayak A, Langdon RB. Montelukast in the treatment of allergic rhinitis: an evidence-based review. Drugs 2007; 67: 887-901.
68. Rodrigo GJ, Yanez A. The role of antileukotriene therapy in seasonal allergic rhinitis: a systematic review of randomized trials. Ann Allergy Asthma Immunol 2006; 96: 779-786.
69. Ribeiro JD, Toro AAD, Baracat ECE. Antileukotrienes in the treatment of asthma and allergic rhinitis. J Pediatr (Rio J) 2006; 82(5): S213-S221.
70. Mucha SM, de Tineo N, Naclerio RM, et al. Comparison of montelukast and pseudoephedrine in the treatment of allergic rhinitis. Arch Otolaryngol Head Neck Surg 2006; 132: 164-172.
71. Nayak A. A review of montelukast in the treatment of asthma and allergic rhinitis. Expert Opin Pharmacother 2004; 5: 679-686.
72. Jayasekera NP, Toma TP, Williams A, et al. Mechanisms of immunotherapy in allergic rhinitis. Biomed Pharmacother 2007; 61: 29-33.
73. Calderon MA, Alves B, Jacobson M, et al. Allergen injection immunotherapy for seasonal allergic rhinitis (review). Cochrane Database Syst Rev 2007; (1): CD001936.
74. Eng PA, Reinhold M, Gnehm HP. Long term efficacy of preseasonal grass pollen immunotherapy in children. Allergy 2002; 57: 306-312.
75. Cox L. Sublingual immunotherapy in pediatric allergic rhinitis and asthma: Efficacy, safety, and practical considerations. Curr Allergy Asthma Rep 2007; 7: 410-420.
76. Wilson DR, Torres LI, Durham SR. Sublingual immunotherapy for allergic rhinitis (review). Cochrane Database Syst Rev 2003; 2: CD002893.
77. Penagos M, Compalati E, Tarantini F, et al. Efficacy of sublingual immunotherapy in the treatment of allergic rhinitis in pediatric patients 3 to 18 years of age: A meta-analysis of randomized, placebo-controlled, double-blind trials. Ann Allergy Asthma Immunol 2006; 97: 141-148.
78. Didier A, Malling HJ, Worm M, et al. Optimal dose, efficacy, and safety of once-daily sublingual immunotherapy with a 5-grass pollen tablet for seasonal allergic rhinitis. J Allergy Clin Immunol 2007; 120: 1338-1345.
79. Fiocchi A, Pajno G, L Grutta S, et al. Safety of sublingual-swallow immunotherapy in children aged 3 to 7 years. Ann Allergy Asthma Immunol 2005; 95: 254-258.
80. Passalacqua G, Ciprandi G. Novel therapeutic interventions for allergic rhinitis. Expert Opin Investig Drugs 2006; 15: 1615-1625.
81. Wilson DR, Torres LI, Durham SR. Sublingual immunotherapy for allergic rhinitis: Systematic review and meta-analysis. Allergy 2005; 60: 4-12.
82. Keskin O, Tuncer A, Adalioglu G, et al. The effects of grass pollen allergoid immunotherapy on clinical and immunological parameters in children with allergic rhinitis. Pediatr Allergy Immunol 2006; 17: 396-407.
83. Casanovas M, Fernández-Caldas E, Alamar R, et al. Comparative study of tolerance between unmodified and high doses of chemically modified allergen vaccines of Dermatophagoides pteronyssinus. Int Arch Allergy Immunol 2005; 137: 211-218.
84. Corrigan CJ, Kettner J, Doemer C, et al. Efficacy and safety of preseasonal-specific immunotherapy with an aluminium-adsorbed six-grass pollen allergoid. Allergy 2005; 60: 801-807.
85. Baena-Cagnani CE, Passalacqua G, Gómez M, et al. New perspectives in the treatment of allergic rhinitis and asthma in children. Curr Opin Allergy Clin Immunol 2007; 7: 201-206.
86. Chervinsky P, Kunjibettu S, Miller DL, et al. Long-term safety and efficacy of intranasal ciclesonide in adult and adolescent patients with perennial allergic rhinitis. Ann Allergy Asthma Immunol 2007; 99: 69-76.
87. Ratner PH, Wingertzahn MA, van Bavel JH, et al. Efficacy and safety of ciclesonide nasal spray for the treatment of seasonal allergic rhinitis. J Allergy Clin Immunol 2006; 118: 1142-1148.
88. Kaliner MA. Pharmacologic characteristics and adrenal suppression with newer inhaled corticosteroids: A comparison of ciclesonide and fluticasone propionate. Clin Ther 2006; 28: 319-331.
89. Nave R, Wingertzahn MA, Brookman S, et al. Safety, tolerability, and exposure of ciclesonide nasal spray in healthy and asymptomatic subjects with seasonal allergic rhinitis. J Clin Pharmacol 2006; 46: 461-467.
90. Szefler S, Rohatagi S, Williams J, et al. Ceclesonide, a novel inhaled steroid, does not affect hypothalamic-pituitary-adrenal axis function in patients with moderate-to-severe persistent asthma. Chest 2005; 128: 1104-1114.
91. Ahlstrom-Emanuelsson C, Andersson M, Persson C, et al. Topical treatment with aqueous solutions of rofleponide palmitate and budesonide in a pollen-season model of allergic rhinitis. Clin Exp Allergy 2004; 34: 731-735.
92. Chaudry, I.: US20080058295 (2008).
93. Holgate S, Djukanovic R, Casale T, et al. Antiimmunoglobulin E treatment with omalizumab in allergic diseases: An update on anti-inflammatory activity and clinical efficacy. Clin Exp Allergy 2005; 35: 408-416.
94. Adelroth E, Rak S, Haahtela T, et al. Recombinant humanized mAb-E25, an anti-IgE mAb, in birch pollen-induced seasonal allergic rhinitis. J Allergy Clin Immunol 2000; 106: 253-259.
95. Casale TB, Condemi J, LaForce C, et al. Effect of omalizumab on symptoms of seasonal allergic rhinitis: A randomized controlled trial. JAMA 2001; 286: 2956-2967.
96. Morjaria JB, Gnanakumaran G, Babu KS, et al. Anti-IgE in allergic asthma and rhinitis: an update. Expert Opin Biol Ther 2007; 7: 1739-1747.
97. Stock P, Rolinck-Werninghaus C, Wahn U, et al. The role of anti-IgE therapy in combination with allergen specific immunotherapy for seasonal allergic rhinitis. Biodrugs 2007; 21: 403-410.
98. Bousquet J, van Cauwenberge P, Khaled NA, et al. Pharmacologic and anti-IgE treatment of allergic rhinitis ARIA update (in collaboration with GA2LEN). Allergy 2006; 61: 1086-1096.
99. Berger WE. Treatment of allergic rhinitis and other immunoglobulin E-mediated diseases with anti-immunoglobulin E antibody. Allergy Asthma Proc 2006; 27: S29-S32.
100. Vignola AM, Humbert M, Bousquet J, et al. Efficacy and tolerability of anti-immunoglobulin E therapy with omalizumab in patients with concomitant allergic asthma and persistent allergic rhinitis: SOLAR. Allergy 2004; 59: 709-717.
101. Creticos PS, Schroeder JT, Hamilton RG, et al. Immunotherapy with a ragweed-toll-like receptor 9 agonist vaccine for allergic rhinitis. N Engl J Med 2006; 355: 1445-1455.
102. Simons FE, Shikishima Y, van Nest G, et al. Selective immune redirection in humans with ragweed allergy by injecting Amb a 1 linked to immunostimulatory DNA. J Allergy Clin Immunol 2004; 113: 1144-1151.
103. Zhang, K., Saxon, A.: WO2007123771(2007).